Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments

Nikolaos I. Kanellakis, Rachelle Asciak, Megat Abd Hamid, Xuan Yao, Mark McCole, Simon J. McGowan, Elena Seraia, Stephanie B. Hatch, Rob Hallifax, Rachel Mercer,

Thorax · 2020 · 11 citations · 5 references

DOIFull text

Open access

Concepts

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive cancer, associated with poor prognosis. We assessed the feasibility of patient-derived cell cultures to serve as an ex vivo model of MPM. Patient-derived MPM cell cultures (n=16) exhibited stemness features and reflected intratumour and interpatient heterogeneity. A subset of the cells were subjected to high-throughput drug screening and coculture assays with cancer-specific cytotoxic T cells and showed diverse responses. Some of the biphasic MPM cells were capable of processing and presenting the neoantigen SSX-2 endogenously. In conclusion, patient-derived MPM cell cultures are a promising and faithful ex vivo model of MPM.

References

5